ANI Pharmaceuticals Q4 2025: Strong Growth, But Execution Risks Emerge

ANI Pharmaceuticals delivered strong Q4 and FY25 results, with revenue up 30% and record Cortrophin Gel growth. Read why ANIP stock is rated a hold.

London’s ‘jackpot’ Too Good To Go bag is just £4 from Kensington Palace

It's cheaper than Gail's.